Lupin had a good numbers in terms of sales i.e 41% growth QoQ. The net profits saw a growth of 56% QoQ.
Key Takeaways:
- Operating Margin went up from 22.92% to 24.89%. Which is a marginal increase, but an increase nevertheless.
- Expenditure on R&D has increased substantially by 59.52% QoQ and currently stands at 499.4 Crs.
- Finance Cost has gone up substantially, up by 4.55 times. Increase in finance costs was mainly due to acquisition of Gavis, most of which was funded by debt.
- Lupin has paid 23.65% of PBT as taxes for the reported period compared to 28.50% for the same quarter previous year.
- Lupin’s 180 days exclusivity of generic drug of Glumetza expired on Aug 2,2016.
- Lupin has received an Establishment inspection Report for its Goa facility, regarding an inspection done in July Last year.
- Inspection done in March for the Goa Facility, the EIR is till pending.
The share price tumbled down by 5.52% to close at Rs 1599.90. This has been explained in online channels as not meeting expectations. But you know how markets are!
You might also like:
- Lupin Pharmaceuticals slapped form 483 for Goa facility
- Lupin’s tussle with the FDA and Investors – a lesson for the Pharma Industry
- Dr. Lal PathLabs grows at 30%, increasing stake in subsidiaries : Result Analysis
- Karnataka Bank Net Profit Up By 11%, Net NPAs Rise to 2.6%: Result Analysis
- Optionalysis: Making Money When Markets Fall
- Delivery Shockers – 01/03: Thomas Cook, Future Lifestyle and Speciality Restaurants Show up in Today’s Shockers
Disclaimer
Nothing in this newsletter is financial advice and should not be construed as such. Please do not take trading decisions based solely on the matter above; if you do, it is entirely at your own risk without any liability to Capital Mind. This is educational or informational matter only, and is provided as an opinion.
Disclosure: The authors at Capital Mind have positions in the market and some of them may support or contradict the material given above, or may involve a direction derived from independent analysis.
